S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27

Accuray Stock Forecast, Price & News

+0.08 (+2.01 %)
(As of 10/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume355,309 shs
Average Volume750,072 shs
Market Capitalization$368.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Accuray logo

About Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$396.29 million
Cash Flow
$0.13 per share
Book Value
$0.74 per share


Net Income
$-6.31 million




Market Cap
$368.89 million
Next Earnings Date
11/3/2021 (Confirmed)

Social Links


Overall MarketRank

1.92 out of 5 stars

Medical Sector

671st out of 1,358 stocks

Surgical & Medical Instruments Industry

65th out of 124 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Accuray (NASDAQ:ARAY) Frequently Asked Questions

Is Accuray a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray
or view top-rated stocks.

What stocks does MarketBeat like better than Accuray?

Wall Street analysts have given Accuray a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accuray wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Accuray

How can I listen to Accuray's earnings call?

Accuray will be holding an earnings conference call on Wednesday, November 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10161091".

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) announced its quarterly earnings results on Tuesday, August, 10th. The medical equipment provider reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The medical equipment provider earned $110.94 million during the quarter, compared to the consensus estimate of $101.65 million. Accuray had a negative net margin of 1.59% and a positive trailing twelve-month return on equity of 4.91%. During the same period in the prior year, the company posted ($0.01) earnings per share.
View Accuray's earnings history

How has Accuray's stock been impacted by COVID-19?

Accuray's stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARAY shares have increased by 78.9% and is now trading at $4.06.
View which stocks have been most impacted by COVID-19

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2022 earnings guidance on Thursday, October, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $420 million-$427 million, compared to the consensus revenue estimate of $415.82 million.

Who are Accuray's key executives?

Accuray's management team includes the following people:
  • Joshua H. Levine, Chief Executive Officer & Director (LinkedIn Profile)
  • Suzanne C. Winter, President
  • Michael Hoge, Senior Vice President-Global Operations
  • Jean-Philippe Pignol, Senior VP, Chief Medical & Technology Officer
  • Jesse Chew, Secretary, Senior VP & General Counsel

What is Joshua Levine's approval rating as Accuray's CEO?

78 employees have rated Accuray CEO Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among Accuray's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Foundry Partners LLC (0.75%) and Assenagon Asset Management S.A. (0.52%). Company insiders that own Accuray stock include Andrew J Kirkpatrick, Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joseph E Whitters, Joshua Levine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends for Accuray

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have sold Accuray company stock in the last year include Brandon W Green, Jesse Chew, Joshua Levine, Shigeyuki Hamamatsu, and Suzanne C Winter.
View insider buying and selling activity for Accuray
or view top insider-selling stocks.

Which major investors are buying Accuray stock?

ARAY stock was bought by a variety of institutional investors in the last quarter, including Foundry Partners LLC. Company insiders that have bought Accuray stock in the last two years include Byron C Scott, Joseph E Whitters, and Joshua Levine.
View insider buying and selling activity for Accuray
or or view top insider-buying stocks.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $4.06.

How much money does Accuray make?

Accuray has a market capitalization of $368.89 million and generates $396.29 million in revenue each year. The medical equipment provider earns $-6.31 million in net income (profit) each year or $0.04 on an earnings per share basis.

How many employees does Accuray have?

Accuray employs 932 workers across the globe.

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.

When was Accuray founded?

Accuray was founded in 1990.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

Where are Accuray's headquarters?

Accuray is headquartered at 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at (408) 716-4600 or via email at [email protected].

This page was last updated on 10/22/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.